Skip to content

Study · Not a test of the peptide alone · 2025

7 results

Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension : a systematic review.

Ognard J, Alipour Khabir S, Ghozy S, El Hajj G, Kallmes KM, Chen JJ, Kadirvel R, Kallmes DF, Brinjikji W

The journal of headache and pain7 Oct 2025Cited by 3 (Europe PMC)

PMID41057780 (opens in a new tab)PMCIDPMC12502165 (opens in a new tab)DOI10.1186/s10194-025-02148-3 (opens in a new tab)PepBankPUB-41057780
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with idiopathic intracranial hypertension, pooled GLP-1 receptor agonist use (including semaglutide) was associated with improvements in headache frequency.

    In plain wordsIn adults with IIH, use of GLP-1 type drugs as a group was linked to fewer headaches.

    Peptide
    Semaglutide
    Outcome
    DecreaseHeadache frequency
    Study

    n: not reported in source

    Outcome group
    Pain · Nervous system and cognition

    Source sentences

    Summary
    GLP-1 RA use was consistently associated with improvements in headache frequency, weight reduction, and reduced need for acetazolamide or surgical interventions.
    1 context sentence
    Summary · context
    Nine clinical studies (one RCT, eight observational studies) with IIH patients receiving GLP-1 RAs were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with idiopathic intracranial hypertension, pooled GLP-1 receptor agonist use (including semaglutide) was associated with weight reduction.

    In plain wordsIn adults with IIH, use of GLP-1 type drugs as a group was linked to weight loss.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight reduction
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    GLP-1 RA use was consistently associated with improvements in headache frequency, weight reduction, and reduced need for acetazolamide or surgical interventions.
    1 context sentence
    Summary · context
    Nine clinical studies (one RCT, eight observational studies) with IIH patients receiving GLP-1 RAs were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with idiopathic intracranial hypertension, pooled GLP-1 receptor agonist use (including semaglutide) was associated with reduced need for acetazolamide or surgical interventions.

    In plain wordsIn adults with IIH, use of GLP-1 type drugs as a group was linked to less need for acetazolamide or surgery.

    Peptide
    Semaglutide
    Outcome
    DecreaseNeed for acetazolamide or surgical intervention
    Study

    n: not reported in source

    Outcome group
    Patterns of use · Nervous system and cognition

    Source sentences

    Summary
    GLP-1 RA use was consistently associated with improvements in headache frequency, weight reduction, and reduced need for acetazolamide or surgical interventions.
    1 context sentence
    Summary · context
    Nine clinical studies (one RCT, eight observational studies) with IIH patients receiving GLP-1 RAs were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with idiopathic intracranial hypertension, several studies of pooled GLP-1 receptor agonists reported papilledema resolution.

    In plain wordsIn adults with IIH, several studies of GLP-1 type drugs reported that optic disc swelling went away.

    Peptide
    Semaglutide
    Outcome
    IncreasePapilledema resolution
    Study

    n: not reported in source

    Outcome group
    Vision and retina · Eye

    Source sentences

    Summary
    Several studies reported papilledema resolution and a lower risk of visual deterioration.
    1 context sentence
    Summary · context
    Nine clinical studies (one RCT, eight observational studies) with IIH patients receiving GLP-1 RAs were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with idiopathic intracranial hypertension, several studies of pooled GLP-1 receptor agonists reported a lower risk of visual deterioration.

    In plain wordsIn adults with IIH, several studies of GLP-1 type drugs reported a lower risk of worse vision.

    Peptide
    Semaglutide
    Outcome
    DecreaseRisk of visual deterioration
    Study

    n: not reported in source

    Outcome group
    Vision and retina · Eye

    Source sentences

    Summary
    Several studies reported papilledema resolution and a lower risk of visual deterioration.
    1 context sentence
    Summary · context
    Nine clinical studies (one RCT, eight observational studies) with IIH patients receiving GLP-1 RAs were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  6. 06HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with idiopathic intracranial hypertension, cognitive function either improved or remained stable with pooled GLP-1 receptor agonists.

    In plain wordsIn adults with IIH, thinking skills improved or stayed the same with GLP-1 type drugs as a group.

    Peptide
    Semaglutide
    Outcome
    MixedCognitive function
    Study

    n: not reported in source

    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    Cognitive function either improved or remained stable.
    1 context sentence
    Summary · context
    Nine clinical studies (one RCT, eight observational studies) with IIH patients receiving GLP-1 RAs were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  7. 07HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In adults with idiopathic intracranial hypertension, adverse effects of pooled GLP-1 receptor agonists were mostly mild gastrointestinal symptoms, and no serious safety concerns emerged.

    In plain wordsIn adults with IIH, side effects of GLP-1 type drugs as a group were mostly mild gut symptoms, with no serious safety concerns.

    Peptide
    Semaglutide
    Outcome
    No significant changeAdverse effects
    Study

    n: not reported in source

    Outcome group
    Adverse events · Gastrointestinal

    Source sentences

    Summary
    Adverse effects were mostly mild gastrointestinal symptoms; no serious safety concerns emerged.
    1 context sentence
    Summary · context
    Nine clinical studies (one RCT, eight observational studies) with IIH patients receiving GLP-1 RAs were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Versions 2 to 3

    9 Oct 2026, 03:07 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.